PureTech Health (PRTC) investor relations material

Business model and strategy

• Operates a hub-and-spoke biopharma model, spinning out innovative drug programs into independent entities while retaining significant equity and economic interests.

• Focuses on advancing assets with proven human pharmacology, often repurposing or improving drugs previously shelved or underutilized.

• Achieved three FDA approvals, including a first-in-class schizophrenia treatment, and successfully spun out Karuna, acquired for $14 billion.

• Maintains a self-funding model with $320 million in cash and no near-term need for capital raises.

• Prioritizes spinning out Celea and Gallop, with Celea's spin-out expected in the first half of the year and Gallop's by 2026.

Pipeline and clinical progress

• Celea Therapeutics is advancing deupirfenidone for idiopathic pulmonary fibrosis (IPF), with phase 2b data showing strong efficacy and a phase 3 trial planned for the first half of the year.

• The phase 3 trial for deupirfenidone will be a 52-week, head-to-head superiority study against pirfenidone, focusing on forced vital capacity as the primary endpoint.

• Deupirfenidone demonstrated a 50% greater effect size than pirfenidone in phase 2, with favorable tolerability and potential to address a large, underserved patient population.

• Gallop Oncology is developing LYT-200, a galectin-9 antibody for AML and high-risk MDS, with phase 1 results expected soon, focusing on safety, response rates, and overall survival.

• Seaport Therapeutics leverages the Glyph platform for lymphatic drug delivery, aiming to improve CNS drug profiles and expand market access, with PureTech retaining a significant equity stake and future royalty streams.

Market positioning and future outlook

• Deupirfenidone is positioned to potentially become the new standard of care in IPF, with strong differentiation and potential for combination therapy.

• Significant interest from commercial partners and investors, especially for combination opportunities with deupirfenidone.

• The business model allows for monetization of royalties and milestones or continued income streams, providing funding flexibility and value creation.

• Future innovation will focus on small molecules and biologics, particularly in CNS, pulmonary, and immunology, using a cycle of clinical validation and problem-solving to advance assets.

• Over the next 18–24 months, expects to see further spin-outs, maturation of existing programs, and the emergence of a new wave of internally derived assets.